Business Context and Reporting Period
Company: Profound Medical Corp. (Profound)
Reporting Period: Quarter ended March 31, 2026 (Q1 2026)
Filing Type: Form 10-Q (Voluntary filing by Foreign Private Issuer)
Business Overview: Profound is a commercial-stage medical device company developing AI-powered, MRI-guided, incision-free therapies. Its lead product, TULSA-PRO, treats prostate conditions, while Sonalleve treats uterine fibroids and bone metastases. The company operates globally with significant revenue from Canada, the USA, and Germany.
Key Financial Metrics
| Metric (USD in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | 5,337 | 2,621 |
| Gross Profit | 3,832 | 1,853 |
| Gross Margin | 72% | 71% |
| Operating Loss | (8,021) | (11,166) |
| Net Loss | (7,053) | (10,724) |
| Loss Per Share (Basic/Diluted) | $0.19 | $0.36 |
| Cash and Equivalents (End of Period) | 50,295 | 46,433 |
| Long-Term Debt | 4,503 | 4,499 |
| Net Cash Used in Operating Activities | (8,583) | (8,283) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 104% to $5.3 million, driven by a 249% surge in capital equipment sales ($2.9M vs $0.8M) and a 37% increase in recurring non-capital revenue ($2.5M vs $1.8M).
- Expense Reduction: Total operating expenses decreased 9% to $11.9 million. Selling, General, and Administrative (SG&A) expenses dropped 20% due to reduced salaries, commissions, and insurance premiums. Research and Development (R&D) expenses increased 9% due to higher headcount and consulting fees, offset by lower clinical trial costs.
- Improved Loss Profile: Net loss decreased 34% to $7.1 million, primarily due to higher gross profit and reduced SG&A expenses.
- Foreign Exchange: The company recorded a $0.6 million foreign exchange gain, compared to a $0.04 million gain in the prior year, attributed to fluctuations in EUR and CAD rates.
Outlook, Risks, and Management Commentary
- Liquidity: Management expects existing cash ($50.3M) and product sales to fund operations for at least the next 12 months. Proceeds from a December 2025 offering ($40.8M net) are being utilized for TULSA-PRO commercialization and Sonalleve development.
- Debt Covenants: The company is in compliance with its CIBC Credit Agreement. A key covenant requires unrestricted cash to be the greater of the six-month EBITDA loss or $10 million. Future compliance depends on achieving specific revenue and EBITDA targets.
- Strategic Focus: Continued investment in commercializing TULSA-PRO in the US and globally, alongside Sonalleve expansion. The company is exploring new markets for Sonalleve, including abdominal cancers.
- Risks: Risks include the need for additional capital if market acceptance is slower than expected, potential dilution from equity financing, and reliance on regulatory approvals. There are no material legal proceedings currently pending.
Investor Verification Checklist
- Covenant Compliance: Verify ongoing adherence to the CIBC Credit Agreement's cash and revenue covenants, specifically the $10M unrestricted cash floor.
- Revenue Sustainability: Assess the mix of capital vs. recurring revenue to determine the sustainability of the 104% revenue growth rate.
- Cash Burn Rate: Monitor the net cash used in operating activities ($8.6M for the quarter) against the $50.3M cash balance to validate the 12-month runway projection.
- Geographic Concentration: Review revenue concentration risks, noting that Canada and the USA accounted for the vast majority of Q1 2026 revenue.